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Background: The benefits associated with some cancer treatments do not come without risk. A serious side effect of
some common cancer treatments is cardiotoxicity. Increased recognition of the public health implications of cancer
treatment-induced cardiotoxicity has resulted in a proliferation of systematic reviews in this field to guide practice.
Quality appraisal of these reviews is likely to limit the influence of biased conclusions from systematic reviews that have
used poor methodology related to clinical decision-making. The aim of this meta-review is to appraise and synthesise
evidence from only high quality systematic reviews focused on the prevention, detection or management of cancer
treatment-induced cardiotoxicity.
Methods: Using Cochrane methodology, we searched databases, citations and hand-searched bibliographies. Two
reviewers independently appraised reviews and extracted findings. A total of 18 high quality systematic reviews were
subsequently analysed, 67 % (n = 12) of these comprised meta-analyses.
Results: One systematic review concluded that there is insufficient evidence regarding the utility of cardiac
biomarkers for the detection of cardiotoxicity. The following strategies might reduce the risk of cardiotoxicity: 1)
The concomitant administration of dexrazoxane with anthracylines; 2) The avoidance of anthracyclines where possible;
3) The continuous administration of anthracyclines (>6 h) rather than bolus dosing; and 4) The administration of
anthracycline derivatives such as epirubicin or liposomal-encapsulated doxorubicin instead of doxorubicin. In terms of
management, one review focused on medical interventions for treating anthracycline-induced cardiotoxicity during or
after treatment of childhood cancer. Neither intervention (enalapril and phosphocreatine) was associated with
statistically significant improvement in ejection fraction or mortality.
Conclusion: This review highlights the lack of high level evidence to guide clinical decision-making with respect to the
detection and management of cancer treatment-associated cardiotoxicity. There is more evidence with respect to the
prevention of this adverse effect of cancer treatment. This evidence, however, only applies to anthracycline-based
chemotherapy in a predominantly adult population. There is no high-level evidence to guide clinical decision-making
regarding the prevention, detection or management of radiation-induced cardiotoxicity.
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Numerous factors, such as the introduction of screening
programs to facilitate early detection [1, 2], improved
diagnostic imaging, advances in therapy and the imple-
mentation of multidisciplinary cancer care [3], have con-
tributed to improved cancer survival rates over recent
decades [4, 5]. Advances in chemo- and radiotherapy
have had the most impact on cancer survival [6]. The
benefits associated with some cancer treatments, how-
ever, do not come without risk. A devastating side effect
of some common cancer treatments is cardiotoxicity-
principally heart failure. The risk of cardiotoxicity varies
according to the type and intensity of cancer treatment.
Heart failure incidence rates associated with the
commonly-prescribed chemotherapy agents include
0.14–48 % for anthracyclines (estimated risk for doxo-
rubicin dose > 400 mg/m [2] ranges from 0.14 % to 5 %;
for 550 mg/m2 it ranges from 7 % to 26 %, and for
700 mg/m2 the estimated risk ranges from 18 % to 48 %)
[7]. For high dose cyclophosphamides the risk ranges
from 7 to 28 % for high-dose cyclophosphamides [8].
The risk is 1 % for trastuzamab (while 5 % of patients
develop systolic dysfunction, only 1 % develop symptom-
atic cardiomyopathy) [7, 9]; and 8 to 12.5 % for tyrosine
kinase inhibitors [10, 11]. Cardiotoxicity, which can
occur up to 20 years after treatment [12, 13] is likely to
become even more prevalent as the cancer population
ages and novel, so-called ‘targeted’ treatment regimens
that cause damage to cardiac myocytes are more com-
monly employed. Concomitant chest irradiation in
blood, breast and lung cancers is also implicated in car-
diotoxicity [14].
Growing recognition of the longer-term public health
implications of this problem, which is expected to in-
crease as more people successfully complete acute can-
cer treatment, has resulted in a great deal of research in
this field. Two key strategies are commonly utilised to
support implementation of evidence into clinical prac-
tice; clinical practice guidelines and literature reviews
(including both systematic and non-systematic review
methodology). Guidelines for preventing, monitoring
and treating cancer treatment-induced cardiotoxicity are
available [8]. Non-systematic reviews have been published
to support clinical practice and research related to cancer
treatment-induced cardiotoxicity [15]. In addition, a num-
ber of systematic reviews have been published on this
issue. However, critical appraisal and synthesis of system-
atic reviews and meta-analyses is needed in order to en-
sure that decision-making is informed by the best
available accumulated evidence [16]. The ‘meta-review’
employs a unique review methodology in which the find-
ings presented in individual systematic reviews and meta-
analyses are appraised and synthesized. Methods similar
to a traditional systematic review, such as comprehensiveliterature searches and quality assessment by two re-
viewers, are used. The difference between a traditional
systematic review, which may or may not also incorporate
meta-analysis, is that a meta-review only considers results
reported in systematic reviews and meta-analyses, not re-
sults from individual studies. We conducted a meta-
review of the systematic reviews and meta-analyses that
have addressed the important issue of cancer treatment-
induced cardiotoxicity. Our aim was to appraise and syn-
thesise the systematic reviews that have focused on the
prevention, early detection and management of cancer
treatment-induced cardiotoxicity in order to aid policy
and practice decision-making.Methods
Cochrane methodology was used to appraise and synthe-
sise systematic reviews in this field [6]. Our meta-review
included a comprehensive literature search. The relevant
reviews identified were then analysed by categorising
and comparing the populations, interventions, compari-
sons and outcomes that were reported for each review.
In addition, the quality of each review was appraised
using a validated tool [16].Information sources and search strategy
The following databases were searched: CINAHL;
Cochrane Database of Systematic Reviews; Joanna
Briggs Institute library of systematic reviews; EMBASE;
Health source nursing/academic edition; and MED-
LINE. The database searches were supplemented with
manual searching of reference lists plus a forward cit-
ation search using Google Scholar. Only reviews pub-
lished in peer-reviewed journals were included in this
review [17]. Census dates from January 1996 and Octo-
ber 2013 (inclusive) were set for all literature searches.
Only articles written in full-text English were included
[18]. Potentially relevant publications were retrieved in
full-text for review purposes. The search used Boolean
operators to combine free text terms and/or MeSH
terms including cardiotoxicity and systematic review.
An example of the search terms used in one of the da-
tabases searched is presented in Additional File 1.Study selection
Titles and abstracts were screened to eliminate irrelevant
articles. Potentially eligible publications were retrieved
and the full text version was reviewed in detail. Two re-
viewers independently selected studies for inclusion with
a third independent reviewer was available for arbitra-
tion. Inclusion and exclusion criteria for this meta-
review are outlined in Table 1.
Table 1 Inclusion and exclusion criteria for systematic reviews in this meta-review
Inclusion criteria • Study type: Systematic review of original research (as per the PRISMA statement. A systematic review was defined as a
review with a clearly formulated question that used systematic and explicit methods to identify, select and critically appraise
relevant research and to collect and analyse data from the studies that were included in the review. As such, the review
had to describe a detailed search of the literature for relevant studies and synthesis of results)
• Publication: Full peer-reviewed publication
• Population: Patients with cancer
• Intervention: Any intervention applied to prevent, diagnose or manage cancer treatment-induced cardiotoxicity.
• Comparison: Any comparison.
• Outcome: Cardiotoxicity, as defined by the authors of the original systematic review. Could be clinical diagnosis of heart
failure, heart failure graded by a standardized reporting system, subclinical heart failure (identified by myocardial biopsy,
non-invasive imaging techniques or biomarkers) or adverse cardiac events (myocardial infarction, arrhythmia).
Exclusion criteria • Systematic reviews focused on identifying the incidence of cardiotoxicity associated with particular cancer treatment regimens.
• Poor quality (Literature search was not comprehensive, quality of included studies was not appraised, total AMSTAR score <7)
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In addition to extracting data to describe the character-
istics of each systematic review, such as the number of
studies included, year of publication and the total num-
ber of participants, data about the populations, interven-
tions, comparisons and outcomes were extracted. These
data were extracted with a standardised form developed
specifically for this study by two reviewers.
Quality appraisal
All potentially relevant reviews were appraised by two
independent reviewers for their quality and risk of bias
using the validated AMSTAR tool [16]. The 11 items of
the AMSTAR were developed by building on empirical
data collected with previously developed tools and with
expert opinion. As such, the AMSTAR provided a valid,
standardised method to assess the quality of methods
used to search the literature and combine results, as well
as the comprehensiveness that results of the reviews
were reported [7]. Importantly, the AMSTAR criteria
also provided a standardised method to determine the
extent to which the scientific quality of the studies was
assessed in the systematic reviews. The Cochrane Col-
laboration specify this as an important element to in-
clude in the preparation of a Cochrane overview of
reviews [19]. Our definition of ‘high-quality’ was a re-
view that addressed at least 7 of the 11 AMSTAR cri-
teria. We deemed that setting a cut-off for the total
score to indicate quality was appropriate, as psychomet-
ric testing of the AMSTAR tool revealed that, as each
component score measures a different domain of quality,
the summary score is meaningful [20]. Detailed results
of appraisal of all relevant systematic reviews are pre-
sented in Additional File 2.
Data synthesis
Data extracted from the systematic reviews were cate-
gorised and presented in tables and forest plots. Sum-
mary findings are presented in a narrative synthesis.Results
Overall, 31 publications from 352 citations were identi-
fied as potentially relevant. Of note, 11 relevant system-
atic reviews were judged to be of poor quality according
to the AMSTAR criteria and were therefore excluded
from this meta-review. Eighteen systematic reviews ful-
filled the inclusion and exclusion criteria (Fig. 1).Systematic review characteristics
The majority of reviews included randomized controlled
trials [21–35], with only two reviews (11 %) also includ-
ing prospective cohort designs [36, 37] (Table 2). The
mean number of studies included in the reviews was
14.9 (range = 2–55). The majority of the systematic re-
views (n-12; 67 %) pooled results from individual studies
for meta-analysis [21–26, 28, 30–33]. The reviews that
did not use meta-analysis used a narrative approach to
synthesise the findings (n = 6; 33 %) [27, 34–38]. The
systematic reviews were published from 2004 to 2013.Key findings from systematic reviews
Detection of cancer treatment-induced cardiotoxicity
Only one systematic review focused on interventions to
detect cancer treatment-induced cardiotoxicity [36]. This
systematic review identified one randomized controlled
trial and six cohort studies that investigated the role of
cardiac biomarkers, such as brain natriuretic peptide, in
the early detection of cardiotoxicity in children who re-
ceived anthracycline therapy [36]. The authors reported
that the overall quality of the evidence was poor, due to
a lack of randomized controlled trials and small sample
sizes [36]. Based on these findings, the authors of the
systematic review concluded that no clear recommenda-
tions for practice could be made regarding the use of
cardiac biomarkers for the early detection of anthracy-
cline-induced cardiotoxicity [36]. However, it is important
to note that this review was published in 2007, with the
literature search only current to January 2006.
Fig. 1 Prisma flow chart - search results
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The majority (n = 16; 89 %) of the systematic reviews
investigated strategies to prevent cancer treatment-
induced cardiotoxicity [21–35, 37]. These reviews were
further categorized into the following: Prevention of
1. Cardiotoxicity specifically associated with breast
cancer treatment [21–26]
2. Cardiotoxicity specifically associated with prostate
cancer treatment [27];
3. Anthracycline-induced cardiotoxicity in adult cancer
patients [28, 30–33]
4. Cardiotoxicity through dietary supplementation [34];
and
5. Cancer treatment-induced cardiotoxicity in children
[28, 35, 37].
Prevention-focused systematic reviews reported clin-
ical cardiotoxicity, defined as the diagnosis of heart fail-
ure by a physician or a decline in left ventricular
ejection fraction below 40 %, and sub-clinical cardiotoxi-
city. Definitions of sub-clinical cardiotoxicity varied con-
siderably across reviews. For example, reviews used
histological [30, 31], electrocardiographic [34] or echo-
cardiographic [30–32] measurements to identify the
presence of myocardial necrosis as a marker of sub-
clinical cardiotoxicity.The forest plot presented in Fig. 2 displays the results
from meta-analyses that examined the effectiveness of
different chemotherapy regimens or cardioprotective
agents in the prevention of clinical cardiotoxicity. Differ-
ences between systematic reviews in their definition of
what constituted sub-clinical cardiotoxicity precluded
the formation of a similar figure for this outcome.
Prevention of cardiotoxicity associated with breast cancer
treatment
Two of the breast cancer systematic reviews focused on
taxane-based chemotherapy [21, 22]. In one pooled ana-
lysis of the results of 7 trials, there was no statistically
significant difference in the rate of cardiotoxicity be-
tween adjuvant chemotherapy regimens with or without
taxanes in women with early or operable breast cancer
(OR 0.95; 95 % CI = 0.67–1.36) [21]. An earlier system-
atic review, which also examined the adverse effects of
taxane-based adjuvant chemotherapy in women with
early breast cancer, produced similar results [22]. Meta-
analysis of 6 trials including 11,577 patients of adjuvant
chemotherapy including a taxane revealed that the risk
for development of cardiotoxicity was 11 per 1,000 (95 %
CI = 6–18) [22]. In comparison, the risk for cardiotoxicity
in women with early breast cancer who received adjuvant
chemotherapy without a taxane was 12 per 1,000 [22].
The relative risk was 0.9 (95 % CI = 0.53–1.54) [22]. Of
Table 2 Characteristics of included reviews
Author (Year) PICO Characteristics of
included studies
Intervention details Summary of findings Meta-
analysis
AMSTAR
score
Detection
Bryant et al.
(2007) [36]
P: Children receiving
anthracyclines
• One controlled trial
and 6 cohort studies
• cTnT • C-TnT can be used to assess cardioprotection
using dexrazoxane
n 7
I: Cardiac markers • Published from 1983
to 2005
• echocardiography • ANP and BNP are elevated in children who
received anthracyclines
C: Healthy control group • Length of follow-up
in the studies was not
reported
• ANP, BNP • NT-pro-BNP levels higher in children receiving
anthracyclines and had cardiac dysfunction
compared to those withoutO: Cardiac damagePublish • Serum lipid peroxide
• Serum carnitine
• NT-pro-BNP
Prevention of anthracycline-induced cardiotoxicity
Van Dalen
et al. (2010) [30]
P: Cancer patients • 8 controlled trials • Doxorubicin vs epirubicin • No difference in rate of clinical heart failure
between epirubicin and doxorubicin
(RR = 0.36; 95 % CI = 0.12–1.11)
y 11
I: Anthracycline derivative • Published from
1984 to 2004
• Doxorubicin vs liposomal-
encapsulated doxorubicin
• Lower rate of clinical heart failure (RR = 0.20,
95 % CI 0.05 to 0.75) and subclinical heart
failure (RR = 0.38, 95 % CI 0.24 to 0.59)
associated with liposomal-encapsulated
doxorubicin compared with doxorubicin.
C: Another anthracycline with the
same infusion duration and peak
dose. Other chemotherapy and
radiotherapy involving the
heart region must have been
the same as the intervention
group.
• Median length of
follow-up ranged
from 21 to 41
months
• Epirubicin vs liposomal-
encapsulated doxorubicin
• No significant difference in the occurrence of
clinical and subclinical heart failure between
epirubicin and liposomal-encapsulated
doxorubicin (RR = 1.13, 95 % CI 0.46 to
2.77, p = 0.80).
O: Anthracycline-induced heart
failure, subclinical cardiac
dysfunction, abnormalities in
cardiac function, tumor response,
patient survival, other toxicities,
quality of life.
Van Dalen et al.
(2009) [31]
P: Cancer patients who received
anthracycline chemotherapy
• 11 controlled trials • Infusion duration • In meta-analysis of 5 studies with 557 patients, a
lower rate of clinical heart failure was observed
with an infusion duration of 6 h or longer as
compared to a shorter infusion duration
(RR = 0.27; 95 % CI = 0.09 to 0.81)
y 11
I: Dosage schedule (different peak
dose or infusion duration)
• Published from 1989–2008 • Peak doses (maximal dose
received in one week)
• No significant difference in the occurrence of
heart failure for different peak doses of
anthracyline chemotherapy
C: Same anthracycline derivative
with the same dose. Other
chemotherapy and radiotherapy
involving the heart region must
• Length of follow-up
ranged from 7 days
to median of 9 years.
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Table 2 Characteristics of included reviews (Continued)
have been the same as the
intervention group.
O: heart failure, subclinical cardiac
dysfunction, abnormalities in cardiac
function, tumor response, patient
survival, other toxicities, quality
of life.
Van Dalen et al.
(2011) [29]
P: Cancer patients • 18 controlled trials • N-acetylcysteine Only dexrazoxane showed a statistically
significant cardioprotective effect (Heart
failure RR = 0.29; 95 % CI = 0.20–0.41)
y 11
I: Anthracycline with a cardioprotective
agent
• 1983–2009 • Phenethylamines
C: Anthracycline with or without a
placebo
• Length of follow-up was
not available for most of
the included studies
• Coenzyme Q10
O: Anthracycline-induced heart failure,
subclinical cardiac dysfunction,
abnormalities in cardiac function,
tumor response, patient survival,
other toxicities, quality of life.
• In those that reported
length of follow-up, it
ranged from 6 months
up to 5.2 years.
• Combination of vitamin E,
vitamin C and Nacetylcysteine
• Dexrazoxane
• Amifostine
• Carvedilol
• L-carnitine
Itchaki et al.
2013 [33]
P: advanced follicular lymphoma • 8 RCT conducted
between 1974 and 2011.
• ACR regardless of additional
agents, with or without
radiotherapy.
• No advantage to ACR in overall survival
(HR = 0.99; 95 % CI = 0.77–1.29)
y 11
I: anthacyclines (ACR) • Length of follow-up ranged
from 3 to 5 years in most trials.
• Non-ACR, as a single agent
or multiple agents, regardless
of dose.
• ACR not significantly better than non-ACR in
complete response (RR 1.05;95 % CI 0.94–1.18)
C: non ACR regardless of dose • ACR superior to non-ACR in disease control
(HR = 0.65; 95 %CI = 0.52–0.81)
O: overall survival, Progression free
survival, Complete response,
overall response rate, remission
duration, relapse, disease control,
Quality of life, adverse events.
Increased risk for cardiotoxicity associated
with ACR (RR = 4.55; 95 % CI = 0.92–22.49)
Smith et al.
(2010) [32]
P: child and adult patients with
Breast or ovarian cancer, sarcoma,
non-Hodgkin's or Hodgkin's
lymphoma, myeloma
• 55 RCT Clinical cardiotoxicity (congestive
heart failure)
y 9
I: anthracycline agent in liposomal
or non-liposomal formulation or
another non-anthracycline
containing chemotherapy regimen
• Studies published
between 1985 and 2007
Anthracyclines: doxorubicin,
epirubicin, duanorubicin,
idarubicin.
• Authors reported that outcomes occurred
early and while participants were receiving
treatment except in one study where it was
not clear when cardiotoxicity occurred.
C: anthracycline agent • Length of follow-up
not summarised
• Anthracycline vs no anthracycline (OR 5.43;
95 % CI = 2.34–12.62)
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Table 2 Characteristics of included reviews (Continued)
O: Clinical cardiotoxicity (diagnosis
of chronic heart failure)
• Bolus versus continuous infusion (OR = 4.13;
95 % CI = 1.75–9.72)
Subclinical cardiotoxicity (Reduction
in left ventricular ejection fraction
or abnormality in cardiac function
determined using a diagnostic test)
• Liposomal doxorubicin vs doxorubicin
(OR = 0.18; 95 % CI = 0.08–0.38)
• Epirubicin vs doxorubicin OR = 0.39
(95 % CI = 0.2–0.78)
• Anthracycline vs mitoxantrone OR = 2.88
(95 % CI = 1.29–6.44)
• Dexrazoxane vs no dexrazoxane OR = 0.21
(95 % CI = 0.13–0.33)
• Anthracycline was associated with increased risk
of sub-clinical cardiotoxicity (OR = 6.25;
95 % CI = 2.58–15.13).
• Rate of cardiac deaths in 4 studies was significantly
higher in the anthracycline groups (OR = 4.94;
95 % CI = 1.23–19.87, p = 0.025).
Dietary supplementation
Roffe et al.
(2004) [34]
P: Cancer patients • 6 controlled trials Dose ranged from 30 mg
per day to 240 mg per day
• Significant differences between groups
observed in various ECG measures.
n 7
I: Coenzyme Q10 (1 placebo-controlled,
double-blinded study, 5
open label)
• Effect on heart failure or subclinical cardiac
dysfunction was not reported in the trials
C: Any comparison • Published between
1982 and 1996
O: All outcomes considered • Length of follow-up
was not reported
Prevention of cardiotoxicity associated with
prostate cancer treatment
Shelley et al.
(2008) [27]
P: Hormone-refractory prostate
cancer
• 47 RCT published
between 1977 and 2005
Drug categories included: • Severe cardiovascular toxicity was more common
with Estramustine versus Best Supportive Care or
Hormones.
n 10
I: Chemotherapy • Length of follow up
was not reported
• estramustine, • Similar rates of cardiotoxicity with estramustine
alone and medroxyprogesterone acetate plus
epirubicin.
C: Any comparison • 5-fluorouracil • Cardiotoxicity was less common with epirubicin
(11 %) than doxorubicin (48 %).
O: Overall survival, Disease-specific
survival, PSA response, time to
progression, pain response,
toxicity, quality of life.
• cyclophosphamide • Doxorubicin combined with diethlystilbestrol was
more cardiotoxic than doxorubicin (7 % vs 1 %).
• doxorubicin
• mitoxantrone
• docetaxel
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Prevention in children
Bryant et al.
(2007) [35]
P: Children receiving anthracyclines • 4 controlled trials
published between
1994 and 2004
• Infusion versus rapid bolus
infusion
• No cost-effectiveness data were identified in
the systematic review
n 7
I: Any cardioprotection intervention • Length of follow-up
ranged from 25 to 56
months
• Coenzyme Q10 • There were conflicting results in trials of rapid or
continuous infusion of anthracycline chemotherapy
C: Any comparison • Dexrazoxane • Coenzyme Q10 was examined in one small trial
(n = 20).
O: Mortality, heart failure, arrhythmia,
measures of cardiac function and
cost-effectiveness
• Mean reduction in percentage left ventricular
fraction shortening was lower in the group that
received coenzyme Q10.
• Dexrazoxane was examined in a trial with 105
participants.
• Fewer patients who received dexrazoxane had
elevations in troponin (21 % vs 50 %; p < 0.001)
Sieswerda et al.
2011 [37]
P: children with cancer • 15 observational studies
published between 1998
and 2007
• Different liposomal
anthracyclines looked at
Liposomal daunorubicin,
pegylated liposomal
doxorubicin, liposomal
doxorubicin.
No evidence from controlled trials was identified. n 7
I: liposomal anthracyclines • (9 prospective cohort
studies, 2 retrospective
cohort studies, three case
reports, one unclear
design)
Impossible to know whether there are differences
in outcomes
C: Any comparison • Duration of follow up
was reported in 10
studies (ranged from 1
to 58 months)
O: cardiotoxicity, tumour response,
adverse events
Van dalen et al.
2012 [28]
P: children with cancer • 8 RCT published from
1975 to 2009
1153 treatment, 1121 control. • Rate of cardiac death was similar between
treatment groups in meta-analysis of two trials
(RR = 0.41; 95 % CI = 0.04–3.89)
y 11
I: anthracyclines • Length of follow-up was
not mentioned in the
majority of trials
Culmulative duanorubicin
treatment protocol 90–350
mg/m2.
• No significant difference in HF between treatment
groups in one trial (RR = 0.33; 95 % CI = 0.01–8.02)
C: non anthracycline Peak dose of anthracycline
in one week = 25–90 mg/m2.
doxorubicin treatment
protocol was 300–420 mg/m2.
O: survival Peak dose doxorubicin in 1
week 25–60 mg/m2
Tumour response cardiotoxicity
Prevention of cardiotoxicity associated with
breast cancer treatment
Valachis et al.
(2013) [24]
P: Breast cancer • Pooled OR for CHF in patients with breast cancer
receiving dual anti-HER2 therapy versus anti-HER2
y 8
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Table 2 Characteristics of included reviews (Continued)
• 6 controlled trials that
were all published in
2012.
Anti-HER2 monotherapy
(lapatinib or trastuzumab or
pertuzumab)
monotherapy was 0.58 (95 % CI: 0.26–1.27,
p-value = 0.17)
I: anti-HER2 monotherapy • Length of follow-up was
not reported.
• Pooled OR of LVEF decline with dual anti-HER2
therapy versus anti-HER2 monotherapy was 0.88
(95 % CI: 0.53–1.48, p-value = 0.64)
C: anti-HER2 combination therapy • Comparable cardiac toxicity between these two
therapies
O: LVEF decline less than 50 % or more
than 10 % from baseline, National
Cancer Institute Common Toxicity
Criteria Chronic heart failure grade
3 or more.
Viani et al.
2007
P: HER-2-positive early breast cancer • 5 RCT published in 2005
and 2006
Doxorubicin and
cyclophosphamide
(AC) + paclitaxel (P).
• Meta-analysis of 5 trials of adjuvant trastuzumab
revealed a significant reduction in mortality
(p < 0.00001), recurrence (p < 0.00001), metastases
(p < 0.00001) and second tumours (p =0.007)
compared with no trastuzumab
y 10
I: adjuvant trastuzumab • Length of follow-up
ranged from 9 to 60 months
after randomisation
Docetaxel or vinorelbine +
fluorouracil, epirubicin and
cyclophosphanide.
• Increased cardiotoxicity including symptomatic
cardiac dysfunction and asymptomatic decrease
in LVEF with trastuzumab compared to no
trastuzumab
C: any comparison Doxo, cyclo + trastuz. • The likelihood of cardiac toxicity was 2.45 times
higher for trastuzumab compared with no
trastuzumab (statistically significant heterogeneity)O: mortality, recurrance, metastases,
second tumour no breast cancer rate
Docetaxel, carboplatin +
trastuz.
Cardiac toxicity and brain metastases AC + docetaxel.
Qin et al.
2011 [21]
P: node negative breast cancer • 19 RCT published from
2003 to 2010
Taxane treatment vs non
taxane treatment
• Disease free survival: taxane treatment HR 0.82,
95 % CI 0.76–0.88
y 10
I: adjuvant taxane • Median length of follow-
up ranged from 35 to
102 months
• Overall Survival: HR 0.85, 95 % CI 0.78–0.92
favoured taxane
C: chemo without taxane • increased toxicity for neutropenia (OR = 2.28,
95 % CI 1.25–4.16), fatigue (OR = 2.10, 95 % CI
1.37–3.22), diarrhea (OR = 2.16, 95 % CI 1.32–3.53),
stomatitis (OR 1.68, 95 % CI 1.04–2.71), oedema
(OR 6.61, 95 % CI 2.14–20.49).
O: disease free survival, overall
survival, drug related toxicityof
taxane
• In pooled analysis of results from 7 trials, there
was no statistically significant difference in the
rate of cardiotoxicty between chemotherapy
regimens with or without taxanes (OR 0.95;
95 % CI = 0.67–1.36)
• taxane treatment showed significant reduction
in death and recurrence
Lord et al.
2008 [26]
P: metastatic breast cancer • 34 RCT published
between 1974 and 2004
• Comparison between
anthracyclines and non-
• 23 trials with 4777 patients that compared
anthracycline with non-antitumour antibiotic
regimens reported on cardiotoxicity.
y 10
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Table 2 Characteristics of included reviews (Continued)
antitumour antibiotic
regimens.
I: anti-tumour antibiotics • Length of follow-up was
not reported in most
trials
• Comparison between
mitoxantrone
and non-anti-tumour
antibiotic regimen
• Patients who received anthracyclines were more
likely to develop cardiotoxicity OR = 5.17
(95 % CI = 3.16–8.48)
C: chemo regimens without anti
tumour antibiotics
• Estimated length of
follow-up from survival
curves ranged from 2 to
102 months.
• Overall survival was reported in 23 studies of
anthracyclines. No statistically significant
difference in overall survival was observed
between the regimens (HR 0.97, 95 % CI 0.91–1.04)
O: overall survival, time to progression,
response, quality of life, toxicity
• The rate of cardiotoxicty was not reported in
the mitoxantrone comparison.
Ferguson et al.
2007 [22]
P: breast cancer • 12 RCT published from
2002 to 2006
Any taxane contain regime
vs regimen without taxane
• No difference in the risk of developing
cardiotoxicity between taxane containing
and non-taxane containing regimens (OR 0.90,
95 %CI 0.53 to 1.55) in meta-analysis of 6
studies involving 11557 patients.
y 11
I: chemotherapy with taxane • Length of follow-up was
43 to 69 months.
C: chemotherapy without taxane
O: overall survival, disease free
survival, toxicity, quality of life,
cost effectiveness
Duarte
et al. 2012 [25]
P: breast cancer • 4 RCT published between
2003 and 2009
Combinations Taxane and
anthracycline; anthracycline;
combined neo-adjuvant and
adjuvant chemo; adjuvant vs
non-adjuvant therapy;
granulocyte colony-
stimulation factor; adjuvant
tamoxifan prescribed for 5
years
• Disease free survival: dose dense therapy
significant improvement (HR = 0.83; 95 %
CI = 0.73–0.95)
y 9
I: conventional chemotherapy • Length of follow-up
ranged from 23 to
125 months
• Dose dense chemotherapy not capable of
improving overall survival (HR = 0.86; 95 %
CI 0.73–1.01).
C: aggressive adjuvant chemo • Women who received a dose-dense
chemotherapy regimen were not more likely
to develop cardiotoxicity (OR = 0.5;
95 % CI = 0.05–5.54).
O: overall survival, disease free survival,
incidence of Common Toxicity Criteria
Scale grades 3,4,5
Management
Sieswerda et al.
2011 [38]
P: children with cancer 2 RCT published in 2004
and 2008
• Enalapril Vs placebo • 203 patients in total n 11
I: anthracycline induced cardiotoxicity
medical interventions
• Phosphecreatine vs control
treatment (vitamin C,
adenosine tri-phosphate,
vitamin E, oral
co-enzyme Q10)
Enalapril trial
C: placebo, other medical interventions,
no treatment
• Median follow-up was 2.8 years
O: overall survival, mortality due
to HF, development of HF, adverse
events and tolerability
• One intervention participant developed
clinically significant decline in cardiac
performance compared with 6 control
participants (RR = 0.16, 95 % CI 0.02–1.29).
• Higher occurrence of dizziness or hypotension
(RR 7.17, 95 % CI 1.71 to 30.17) associated
with enalapril
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Table 2 Characteristics of included reviews (Continued)
• Higher occurrence of fatigue associated
with enalapril (p = 0.013).
Phosphocreatine trial
• Length of follow-up estimated to be 15 days
• No deaths in both groups
• No adverse events reported
• no definitive conclusions can be drawn
due to small sample size
Legend: cTnT Cardiac Troponin T, ANP Atrial Natriuretic Peptide, NT-BNP N-terminal Brain Natriuretic Peptide, ACR, anthacyclines, LVEF Left ventricular ejection fraction, HF Heart failure, 95 % CI 95 % Confidence Interval,
RR Relative risk, OR, Odds ratio, HR Hazard ratio, RCT Randomised controlled trial.
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Fig. 2 Summary of meta-analyses of included systematic reviews with clinical heart failure as the outcome
Conway et al. BMC Cancer  (2015) 15:366 Page 12 of 16note, the chemotherapy regimens of control and interven-
tion arms of the studies included in the meta-analyses
contained anthracyclines [21, 22]. As there were no differ-
ences in the rate of cardiotoxicity between participants
who did and did not receive taxanes, it would appear that
the rates of cardiotoxicity were likely due to the use of
anthracyclines.
A specific focus of two further systematic reviews
that examined the prevention of cardiotoxicity associ-
ated with breast cancer treatment investigated the im-
pact of anti-human epidermal growth factor receptor 2
(HER-2) therapy [23, 24]. One systematic review aimed
to determine whether there was an increased risk of
cardiotoxicity in breast cancer patients treated with
dual HER-2 blockade (pertuzumab plus trastuzumab,
or trastuzumab plus lapatanib) compared to monother-
apy (lapatanib or trastuzumab or pertuzumab) [24]. No
statistically significant difference in the likelihood of
developing clinical heart failure or of decline in left
ventricular ejection fraction was identified [24]. The
authors concluded that the evidence supported the useof dual therapy in this population with no adverse cardiac
effects. The second breast cancer systematic review fo-
cused on the anti-HER-2 medication trastuzumab [23].
Meta-analysis indicated that the odds of developing cardi-
otoxicity were 2.45 times higher (95 % CI = 1.89–3.16) in
subjects prescribed trastuzumab [23]. However, overall
mortality, recurrence and mortality rates were de-
creased in subjects who received trastuzamab despite
their higher odds of developing post-treatment cardiac
symptoms. [23] Close monitoring of cardiac function
was recommended, based on these findings.
A systematic review of randomized controlled trials
of dose-dense anthracycline-based chemotherapy in
early breast cancer, comprising a meta-analysis that
combined n = 1,310 patients, revealed that women who
received a dose-dense chemotherapy regimen were not
more likely to develop cardiotoxicity (OR = 0.5; 95 %
CI = 0.05–5.54) [25]. Trials of dose-dense chemother-
apy were defined in this review as the same type and
total amount of the drug administered over a shorter
interval of time [25]. A further systematic review focused
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[26]. The authors recommended careful consideration re-
garding the use of anthracyclines in this population due to
the increased likelihood of developing cardiotoxicity (OR
= 5.17; 95 % CI = 3.16–8.48) [26].
Prevention of cardiotoxicity associated with prostate cancer
treatment
One systematic review addressed the issue of cardiotoxi-
city associated with treatment for hormone-refractory
prostate cancer [27]. While 47 trials met the inclusion
criteria for this review, the chemotherapy regimens in-
vestigated were too dissimilar to conduct meta-analysis
[27]. No specific recommendations for the prevention of
cardiotoxicity in this population were noted by the au-
thors of this review.
Prevention of anthracycline-induced cardiotoxicity in adult
cancer patients
In a systematic review of cardioprotective agents used
during anthracycline therapy, the authors concluded that
of the eight different agents for which there were ran-
domized controlled trials, only dexrazoxane could be
recommended for clinical practice [29]. Conflicting rec-
ommendations were provided in another systematic re-
view by Smith et al. [32], which concluded that the
evidence was not sufficiently robust to support the rou-
tine use of any particular cardioprotective agent, nor a
liposomal formulation or alternative anthracycline treat-
ment regimen. In regard to the use of anthracycline de-
rivatives, a 2010 systematic review by van Dalen et al.
came to a similar conclusion, suggesting that further re-
search is needed to provide recommendations regarding
the use of these alternative chemotherapy regimens [30].
Anthracycline administration considerations were ex-
amined for their potential association with cardiotoxicity
in a second systematic review by van Dalen [31]. This
review identified that continuous anthracycline infusion
(>6 h) rather than bolus injection reduced the risk of
cardiotoxicity [31]. No differences were observed in the
rate of cardiotoxicity as a result of different doxorubicin
peak doses [31].
A recently published review (2013) by Itchaki focused
on anthracycline use in people receiving treatment for
advanced follicular lymphoma [33]. Due to the increased
risk ratio for cardiotoxicity (4.55; 95 % CI = 0.92-22.49)
associated with anthracycline treatment in this popula-
tion, the authors concluded that evidence of the benefit
of anthracyclines in this population is limited [33].
Dietary supplementation
One systematic review appraised randomized and non-
randomized studies that reported the use of coenzyme
Q10 (CoQ10) to reduce the adverse effects of cancertreatment [34]. Only three randomized controlled trials,
which included a total of 140 patients, investigated the
effects of CoQ10 on cardiotoxicity [34]. These trials
were not subjected to meta-analysis. The authors of the
systematic review concluded that CoQ10 could provide
some protection against cardiotoxicity during cancer
treatment based on the fact that significant differences
in electrocardiographic measurements were identified
between control and CoQ10 groups [34]. However, using
CoQ10 in clinical practice was not recommended, due
to insufficient data [34].
Prevention of cancer treatment-induced cardiotoxicity in
children
All of the systematic reviews that focused on the preven-
tion of cardiotoxicity in children addressed this issue as
it related to anthracycline-based chemotherapy. Sies-
werda et al. [37] concluded that randomized controlled
trials are needed to increase understanding of the bene-
fits and risks of liposomal anthracyclines in children, as
the evidence to date solely consists of observational
studies [37]. In a further systematic review, meta-
analysis of two randomized controlled trials revealed no
statistically significant difference in the risk of cardiac
death (RR = 0.4; 95 %CI = 0.04–3.89) or heart failure (RR
= 0.33; 95 %CI = 0.01–8.02) in children who received
anthracyclines [28]. However, the total number of partic-
ipants in the randomized controlled trials was small (n
= 410) [28]. As such, no firm conclusions regarding the
implications for clinical practice were drawn from this
analysis. A further systematic review focused on cardio-
protection in children who received anthracyclines [35].
Based on the fact that only four randomized controlled
trials with methodological limitations met the inclusion
criteria, the authors concluded that there was limited
evidence to guide cardioprotective therapies in this
population and definitive recommendations for practice
could not be made [35].
Management of cancer treatment-induced cardiotoxicity
Only one systematic review focused on interventions to
treat cancer treatment-induced cardiotoxicity [38]. This
review focused on the treatment of anthracycline-
induced cardiotoxicity in children. Only two randomized
controlled trials, which enrolled a total of 203 patients,
were included in this review. The two interventions
tested were enalapril and phosphocreatine. While the
participants who received enalapril were less likely to ex-
perience decline in cardiac function, the difference be-
tween groups was not statistically significant (p < 0.5).
Moreover, participants who received enalapril were more
likely to experience hypotension, dizziness and fatigue.
Therefore, the authors concluded that the benefits of
this therapy be weighed against the greater risk of side
Conway et al. BMC Cancer  (2015) 15:366 Page 14 of 16effects in children with asymptomatic cardiotoxicity [38].
Conclusions regarding the use of phosphocreatine could
not be made due to the high risk of bias. The authors of
the review concluded that further high quality randomized
controlled trials are required in this field [38].
Discussion
This aim of this meta-review was to appraise and syn-
thesise the systematic reviews that have focused on the
prevention, early detection and management of cancer
treatment-induced cardiotoxicity in order to aid policy
and practice decision-making. Based on the 18 system-
atic reviews included in this meta-review that were
deemed to be high quality according to the AMSTAR
criteria, the following conclusions can be drawn. First,
there is insufficient evidence to draw firm conclusions
regarding the utility of cardiac biomarkers for the detec-
tion of cancer treatment-induced cardiotoxicity. Based
on conclusions drawn from systematic reviews focused
on prevention, the following strategies could reduce the
risk of cardiotoxicity: 1) The concomitant administration
of dexrazoxane with anthracylines; 2) The administration
of continuous anthracyclines, preferably for longer than
6 h, rather than bolus dosing; and 3) The administration
of anthracycline derivatives such as epirubicin or
liposomal-encapsulated doxorubicin instead of doxorubi-
cin. In this context, it should be noted that while dexra-
zoxane is listed in the relevant pharmaceutical benefits
scheme in some countries for this indication (e.g. it is
listed as such by the FDA in the USA), in others such as
Australia it is not. Hence its routine use would be prob-
lematic in some countries, as it would be hard to pro-
cure and expensive for patients who already incur
considerable treatment overheads. In addition, in many
high volume chemotherapy facilities it is not logistically
possible to deliver anthracyclines over an extended
period. In the facilities in which this review team work,
for example, 30 min of infusion via a 100 ml minibag is
the norm for reasons of economy and patient
throughput.
There is limited evidence pertaining to the effective-
ness of interventions to manage cancer treatment-
induced cardiotoxicity. While two different medical in-
terventions were identified in a systematic review that
focused on treatment strategies for cardiotoxicity in
childhood cancer (enalapril and phosphocreatine), nei-
ther was associated with statistically significant improve-
ment in ejection fraction or mortality.
The largest number of systematic reviews included in
this meta-review addressed the prevention of cancer
therapy-induced cardiotoxicity. As demonstrated in
Fig. 2, few strategies appear to reduce the risk of devel-
oping clinical heart failure. These included the avoidance
of anthracycline-based chemotherapy (which is routinewhere cardiac risk before therapy is known), the use of
doxorubicin derivatives, a longer anthracycline infusion
duration and concomitant administration of the cardio-
protective agent dexrazoxane. Of note, all meta-analyses
that revealed statistically significant reductions in the
rate of clinical heart failure related specifically to the use
of anthracyclines. This is not surprising, considering
anthracyclines are the focus of the greatest amount of
research in this particular field [7]. However, our meta-
review identified that the Level 1 evidence from meta-
analyses focused on the prevention of cardiotoxicity was
derived from a relatively small number of trials and in
most cases, less than one thousand participants in total.
Therefore, despite the fact that the cardiotoxic effects of
this particular chemotherapy regimen have been known
for a considerable time, there are still gaps in the evi-
dence regarding how to facilitate early detection and
management. In particular, the evidence for strategies
that protect children with cancer from developing car-
diac complications associated with their treatment is
lacking [35].
Of note, one previous overview of systematic reviews
on the topic of cancer treatment-induced cardiotoxicity
has been published [39]. However, this review was
smaller in scope than the present review. It focused only
on the prevention of cardiotoxicity associated with
anthracycline treatment in the paediatric population
[39]. Furthermore, only reviews registered by the
Cochrane Collaboration were included in van Dalen et
al’s systematic review [39]. Excluding all other reviews is
an effective strategy to ensure only high quality system-
atic reviews when detailed quality appraisal is not
employed as part of the meta-review process [40]. It is
possible however that systematic reviews not registered
with the Cochrane Collaboration will meet many
AMSTAR criteria, indicating that sufficient processes
were undertaken to ensure potential sources of bias as-
sociated with the systematic review process were
avoided. Therefore, including only Cochrane reviews in
a meta-review is not the optimal choice when quality ap-
praisal is included as part of the meta-review process.
In regard to the quality of the systematic reviews that
reported data on cardiotoxicity, this meta-review identi-
fied that: 1) the methodology used in a considerable
number of systematic reviews was poor (n = 11; 35 % of
the potentially relevant reviews were excluded due to
low quality according to the AMSTAR criteria); and 2)
half of the systematic reviews not registered with the
Cochrane Collaboration were of high quality (n = 9; 50 %
of reviews that met more than 7 of the AMSTAR criteria
were not Cochrane reviews). Based on these findings, it
is recommended that future meta-reviews that focus on
the prevention, detection and management of cancer
treatment-induced toxicities should not include only
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that potentially contain unbiased and important recom-
mendations for practice could be overlooked. However,
quality appraisal of the systematic reviews would be re-
quired to ensure biased conclusions from systematic re-
views that have used poor methodology are avoided.
Specific deficiencies in Level 1 evidence for the detec-
tion, prevention and management of cancer therapy-
induced cardiotoxicity were identified in this meta-review.
Only one high quality systematic review of dietary supple-
mentation was identified, which was published in 2004.
Recommendations for practice regarding interventions for
the detection of cancer treatment-induced cardiotoxicity
were not able to be drawn from this meta-review. How-
ever, we have identified that an updated systematic review
focusing on the detection of cardiotoxicity is required to
help inform clinical practice, as the only previous high
quality review included evidence up to January 2006. No
Level 1 evidence is available to guide clinical decision-
making regarding the prevention, detection or manage-
ment of radiation-induced cardiotoxicity. While the role
of chest irradiation in inducing cardiotoxicity has been
known for some time, studies to date have focused on
minimizing the dose of radiation to the heart that are not
powered to detect clinical differences in the rate of cardio-
toxicity [14]. The small number of primary research stud-
ies undertaken to investigate strategies to prevent
radiation-induced cardiotoxicity is likely the reason why
no systematic reviews were identified in our literature
search. While an evidence base about the potential effect-
iveness of exercise as an intervention to aid prevention of
cancer treatment-induced cardiotoxicity is also emerging,
similarly, no systematic reviews of the effectiveness of this
intervention were identified in our comprehensive search
of the literature. Based on the positive results observed in
animal studies, it is likely that human clinical trials of ex-
ercise for the prevention of cardiotoxicity associated with
cancer treatment will be reported in the future [41].
Limitations
It should be noted that only English language reviews
were included in our meta-review. However, we consid-
ered this to be acceptable because sensitivity testing re-
garding information published in languages other than
English has shown that English language reviews repre-
sent a robust view of the available evidence base in
health areas [35]. A considerable strength of this meta-
review is that we were able to reduce the risk of bias
from our conclusions regarding the prevention, detec-
tion and management of cancer-treatment induced car-
diotoxicity by including only systematic reviews that had
considered the quality of included studies in making de-
cisions about the validity of the evidence, as well as the
suitability of the included trials for meta-analyses. Noattempts were made to combine data from multiple sys-
tematic reviews, due to the substantial degree of hetero-
geneity between the populations, interventions and
outcomes investigated. As is the case for all meta-
reviews, it should be noted that evidence from recent
studies that were not included in the systematic reviews
was not able to be considered in our review. For this rea-
son, the majority of evidence regarding the detection, pre-
vention and management of cancer treatment-induced
cardiotoxicity included in this meta-review is from studies
conducted at least 5 years ago. Another important point
to note is that absolute risk of cardiotoxicity was not re-
ported in meta-analyses due to heterogeneity between in-
dividual studies.
Conclusion
This meta-review has highlighted the paucity of high
level evidence to guide clinical practice decision-making
regarding the detection and management of cancer
treatment associated cardiotoxicity. There is a greater
amount of evidence available to guide practice in regard
to the prevention of this adverse effect of cancer treat-
ment. It is important to note, however, that the meta-
analyses that revealed statistically significant reductions
in clinical cardiotoxicity only applied to anthracycline
based chemotherapeutic regimens. No high-level evi-
dence is available to guide clinical decision-making re-
garding the prevention, detection or management of
radiation-induced cardiotoxicity.
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